UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000027558
Receipt number R000031498
Scientific Title Multicenter observational study on the connection between sarcopenia and the curability of chemotherapy in advanced or recurrent colorectal cancer.
Date of disclosure of the study information 2017/05/31
Last modified on 2019/07/12 11:08:29

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Multicenter observational study on the connection between sarcopenia and the curability of chemotherapy in advanced or recurrent colorectal cancer.

Acronym

Multicenter observational study on the connection between sarcopenia and the curability of chemotherapy in advanced or recurrent colorectal cancer.

Scientific Title

Multicenter observational study on the connection between sarcopenia and the curability of chemotherapy in advanced or recurrent colorectal cancer.

Scientific Title:Acronym

Multicenter observational study on the connection between sarcopenia and the curability of chemotherapy in advanced or recurrent colorectal cancer.

Region

Japan


Condition

Condition

Colorectal Cancer

Classification by specialty

Gastroenterology Gastrointestinal surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

The aim is to investigate the correration of skeletal mass and fat tissue mass calculated by CT with Overall survival, Progression free survival, Response rate, Adverse event rate for the patients registered in KSCC0701, 0801, 0802, 0902, 1002, 1101 who had progressive or reccurent colorectal cancer.

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The primary outcomes are Overall survival period, relapse free survival period, response rate, Adverse event rate. We are going to investigate the correration the sarcopenia, the rate of skeletal muscle loss and subcutaneous or visceral fat with the primary outcomes.

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. The patient is found to have colorectal cancer histopathologically.
2. The tumor is too progressive or reccurent and no resectable. It is judged by the attending doctor.
3. First line systemic chemotherapy is administered.
4. The patients registered in KSCC0701, 0801, 0802, 0902, 1002, 1101 have the image of CT before the start of chemotherapy and 60 to 120 days or 150 to 210 after chemotherapy.

Key exclusion criteria

It is the excluded case that is judged irreverent by the attending doctor.

Target sample size

249


Research contact person

Name of lead principal investigator

1st name Eiji
Middle name
Last name Oki

Organization

Graduate School of Medical Sciences, Kyushu University

Division name

Department of Surgery and Science, Graduate School of Medical Sciences

Zip code

812-8582

Address

3-1-1 Maidashi, Higashi-ku, Fukuoka, Japan

TEL

092-409-3500

Email

sanae.sakamoto@ks-cc.or.jp


Public contact

Name of contact person

1st name KSCC
Middle name
Last name Research Secretariat

Organization

Kyushu Study group of Clinical Cancer

Division name

KSCC Research Secretariat

Zip code

812-8582

Address

3-1-1 Maidashi, Higashi-ku, Fukuoka, Japan

TEL

092-409-3500

Homepage URL


Email

sanae.sakamoto@ks-cc.or.jp


Sponsor or person

Institute

Kyushu Study group of Clinical Cancer

Institute

Department

Personal name



Funding Source

Organization

Kyushu Study group of Clinical Cancer

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kyushu University Ethics Review Board

Address

3-1-1, Maidashi, Higashi-ku, Fukuoka 812-8582, Japan

Tel

092-641-1151

Email

byssien@jimu.kyushu-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

九州大学病院(福岡県)


Other administrative information

Date of disclosure of the study information

2017 Year 05 Month 31 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications


Number of participants that the trial has enrolled

249

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2017 Year 05 Month 24 Day

Date of IRB

2017 Year 08 Month 02 Day

Anticipated trial start date

2017 Year 05 Month 30 Day

Last follow-up date

2019 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Skeletal mass area of lower L3 level(m2), Visceral fat area(m2), Subcutaneous fat area(m2), Abdominal circumference(cm), skeletal mass index(SMI=skeletal mass area/Height2), Visceral fat area(VFA)/Subcutaneous fat area(SFA)

Patients' information
Age, Sex, Birth date, Registered number, Body mass index(BMI=Weight/Height2), Labo data(AST, ALT, ALP, Na, K, Alb, Cr, T.Bil, CEA, CA19-9, WBC, Neut, Plt, Hb)

Disease information of the patients'
Clinical stage before treatment, Location of the tumor, History of surgery for the colorectal cancer(Ope date, The histopathological diagnosis), History of the chemotherapy(Regimen, dose, period, Best overall response)

Treatment outcome
Response rate(RR), Progression free survival(PFS), Overall survival(OS), Adverse event rate




Management information

Registered date

2017 Year 05 Month 31 Day

Last modified on

2019 Year 07 Month 12 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031498


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name